These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36464708)

  • 1. A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.
    Machida M; Yamazaki C; Kouda N; Hanai Y; Sato H; Konda A; Yamagata Y; Itho T; Aisaka H
    J Pharm Health Care Sci; 2022 Dec; 8(1):29. PubMed ID: 36464708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.
    Wu JY; Kang K; Yi J; Yang B
    World J Clin Cases; 2022 Jun; 10(18):6110-6118. PubMed ID: 35949835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma.
    Gianni C; Bronte G; Delmonte A; Burgio MA; Andrikou K; Monti M; Menna C; Frassineti GL; Crinò L
    Front Pharmacol; 2021; 12():672233. PubMed ID: 34456717
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab-Associated Stevens-Johnson Syndrome in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report.
    Sandhu M; Kc B; Bhandari J; Gambhir HS; Farah R
    Cureus; 2023 Jul; 15(7):e41439. PubMed ID: 37546048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color.
    Pierre AB; Jernigan AM; Castellano T
    Gynecol Oncol Rep; 2023 Dec; 50():101290. PubMed ID: 37868017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-induced Stevens-Johnson Syndrome with Severe Ocular Complications.
    Ryu S; Jun I; Kim TI; Seo KY; Kim EK
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1533-1535. PubMed ID: 33826467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies.
    Li X; Lei Y; Liu J; Lin H; Chen K; Yin F; Wang C; Zhang H
    Discov Oncol; 2023 Aug; 14(1):146. PubMed ID: 37553451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer.
    Riano I; Cristancho C; Treadwell T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620914796. PubMed ID: 32207346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report.
    Cao J; Li Q; Zhi X; Yang F; Zhu W; Zhou T; Hou X; Chen D
    Transl Cancer Res; 2021 Aug; 10(8):3870-3876. PubMed ID: 35116686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
    Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab.
    Lopez M; Hagopian G; Doan L; Lee BJ; Rojek NW; Smith J; Ou SI; Demirdag YY; Nagasaka M
    Allergy Asthma Clin Immunol; 2023 Oct; 19(1):93. PubMed ID: 37898814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant for refractory nivolumab-induced pruritus.
    Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
    Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma.
    Li X; Li G; Chen D; Su L; Wang RP; Zhou Y
    Front Oncol; 2023; 13():912168. PubMed ID: 37781182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration.
    de Vries F; Smit AAJ; Wolbink G; de Vries A; Loeff FC; Franssen EJF
    Front Oncol; 2022; 12():960116. PubMed ID: 36713570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of Wnt/β-catenin signaling in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Chen CB; Chang WC; Wu MY; Kao TY; Wang YW; Wang CW; Chen CJ; Chung WH; Su SC
    Int J Biol Sci; 2020; 16(2):353-364. PubMed ID: 31929762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.